Nivolumab plus Ipilimumab in Advanced MelanomaJedd D. Wolchok, Mario Sznol, Harriet M. Kluger et al.|New England Journal of Medicine|2013Cited by 4.2k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015Cited by 1.2k
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancerArvind Ravi, Justin F. Gainor, Natalie I. Vokes et al.|Nature Genetics|2023Cited by 185
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Tony Mok, Naiyer A. Rizvi et al.|Journal of Thoracic Oncology|2022Cited by 72
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastasesBenjamin Izar, Lindsay Caprio, Amit Dipak Amin et al.|Nature Medicine|2025Cited by 53